The cost-effectiveness of percutaneous coronary intervention as a function of angina severity in patients with stable angina

Circulation: Cardiovascular Quality and Outcomes

Volumn 4, Issue 2, 2011, Pages 172-182

  Zhang, Zugui ^a   Kolm, Paul ^a   Boden, William E ^b   Hartigan, Pamela M ^c   Maron, David J ^d   Spertus, John A ^e   O'Rourke, Robert A ^f   Shaw, Leslee J ^g   Sedlis, Steven P ^h   John Mancini, G B ⁱ   Berman, Daniel S ^j   Dada, Marcin ^k   Teo, Koon K ^a   Weintraub, William S ^a  

^a CHRISTIANA CARE HEALTH SYSTEM   (United States)

^b Health System   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g EMORY UNIVERSITY   (United States)

^h Veterans Affairs New York   (United States)

ⁱ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^j CEDARS SINAI MEDICAL CENTER   (United States)

^k MCMASTER UNIVERSITY   (Canada)

more..

Author keywords

Angina; Cost effectiveness; Quality of life; Questionnaires

Indexed keywords

ANTIANGINA PECTORIS AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HEALTH STATUS; HEART INFARCTION; HUMAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SENSITIVITY ANALYSIS; STABLE ANGINA PECTORIS; STROKE;

AGED; ANGINA PECTORIS; ANGIOPLASTY, BALLOON, CORONARY; CARDIOVASCULAR AGENTS; COST-BENEFIT ANALYSIS; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79959757232     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.110.940502     Document Type: Article

References (30)

1. Weaver WD, Simes RJ, Betriu A, Grines CL, Zijlstra F, Garcia E, Grinfeld L, Gibbons RJ, Ribeiro EE, DeWood MA, Ribichini F. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review. JAMA. 1997;278:2093-2098. (Pubitemid 28016233)
2. Parisi AF, Folland ED, Hartigan P; Veterans Affairs ACME Investigators. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. N Engl J Med. 1992;326:10-16.
3. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. Lancet. 1997;350:461-468.
4. Pitt B, Waters D, Brown WV, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS; Atorvastatin versus Revascularization Treatment Investigators. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med. 1999; 341:70-76. (Pubitemid 29314237)
5. Jancin B. Exercise program beat PCI in stable CAD patients. Internal Med News. 2005;38(3):9.
6. Katritsis DG, Ioannidis JP. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: A meta-analysis. Circulation. 2005;111:2906-2912. (Pubitemid 40823048)
7. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-1516. (Pubitemid 46588415)
8. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk W, Knudtson M, Dada M, Casperson P, Harris CL, Spertus JA, Shaw L, Chaitman BR, Mancini GB, Berman DS, Weintraub WS. Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424. Am Heart J. 2006;151:1173-1179. (Pubitemid 44172871)
9. Weintraub WS, Barnett P, Chen S, Hartigan P, Casperson P, O'Rourke R, Boden WE, Lewis C, Veledar E, Becker E, Culler S, Kolm P, Mahoney EM, Dunbar SB, Deaton C, O'Brien B, Goeree R, Blackhouse G, Nease R, Spertus J, Kaufman S, Teo K. Economics methods in the Clinical Outcomes Utilizing percutaneous coronary Revascularization and Aggressive Guideline-driven drug Evaluation (COURAGE) trial. Am Heart J. 2006;151:1180-1185. (Pubitemid 43866611)
10. Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, Weintraub WS, O'Rourke RA, Dada M, Spertus JA, Chaitman BR, Friedman J, Slomka P, Heller GV, Germano G, Gosselin G, Berger P, Kostuk WJ, Schwartz RG, Knudtson M, Veledar E, Bates ER, McCallister B, Teo KK, Boden WE. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008; 117:1283-1291. (Pubitemid 351365675)
11. Weintraub WS, Spertus JA, Kolm P, Maron DJ, Zhang Z, Jurkovitz C, Zhang Z, Jurkovitz C, Zhang W, Hartigan PM, Lewis C, Veledar E, Boden J, Dunbar SB, Deaton C, Kaufman S, O'Rourke RA, Goeree R, Barnett PG, Teo KK, Boden WE. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008;359:677-687.
12. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB, III, Morrison DA, O'Neill WW, Schaff HV, Whitlow PL, Williams DO, Antman EM, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention-summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation. 2006; 113:156-175. (Pubitemid 43958502)
13. Wyrwich KW, Spertus JA, Kroenke K, Tierney WM, Babu AN, Wolinsky FD. Clinically important differences in health status for patients with heart disease: an expert consensus panel report. Am Heart J. 2004; 147:615-622. (Pubitemid 38900445)
14. Weintraub WS, Boden WE, Zhang Z, Kolm P, Zhang Z, Spertus JA, Hartigan PM, Veledar E, Jurkovitz C, Boden J, Maron DJ, O'Rourke RA, Dada M, Teo KK, Goeree R, Barnett PG; Department of Veterans Affairs Cooperative Studies Program No. 424 (COURAGE Trial) Investigators and Study Coordinators. Cost-effectiveness of percutaneous coronary intervention in optimally treated stable coronary patients. Circ Cardiovasc Qual Outcomes. 2008;1:12-20.
15. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
16. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford, UK: Oxford Medical Publications; 1987.
17. Pedersen TR, Kjekshus J, Berg K, Olsson AG, Wilhelmsen L, Wedel H, Pyorala K, Miettinen T, Haghfelt T, Faergeman O, Thorgerisson G, Jonsson B, Schwartz JS. Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. Circulation. 1996;93:1796-1802.
18. Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H; Scandinavian Simvastatin Survival Study Group. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med. 1997;336:332-336. (Pubitemid 27057183)
19. Centers for Medicare and Medicaid Services. https://www.cms.gov/ MedicareFeeforSvcPartsAB/02-MedicareUtilizationforPartA.asp# TopOfPage. Accessed Januray 26, 2011.
20. Efron B, Tibshirani R. An Introduction to the Bootstrap. New York, NY: Chapman and Hall; 1993.
21. Peeters A, Mamun AA, Willekens F, Bonneux L. A cardiovascular life history. A life course analysis of the original Framingham Heart Study cohort. Eur Heart J. 2002;23:458-466. (Pubitemid 35204185)
22. Mahoney EM, Jurkovitz CT, Chu H, Becker ER, Culler S, Kosinski AS, Robertson DH, Alexander C, Nag S, Cook JR, Demopoulos LA, DiBattiste PM, Cannon CP, Weintraub WS. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA. 2002;288:1851-1858. (Pubitemid 35168140)
23. Caro J, Migliaccio-Walle K, Ishak KJ, Weintraub WS. Estimating life-years lost due to atherothrombotic events: flexible survival functions to use in disease modeling [Abstract]. J Am Coll Cardiol. 2004;43:425A.
24. Spertus JA, Salisbury AC, Jones PG, Conaway DG, Thompson RC. Predictors of quality-of-life benefit after percutaneous coronary intervention. Circulation. 2004;110:3789-3794. (Pubitemid 40023977)
25. Arnold SV, Morrow DA, Lei Y, Cohen DJ, Mahoney EM, Braunwald E, Paul S, Chan PS. Economic impact of angina after an acute coronary syndrome. Insights from the MERLIN-TIMI 36 trial. Circ Cardiovasc Qual Outcomes. 2009;2:344-353.
26. Weinstein MC, Stason WB. Cost-effectiveness of coronary artery bypass surgery. Circulation. 1982;66(5 pt 2):III56 -III66.
27. Wong JB, Sonnenberg FA, Salem DN, Pauker SG. Myocardial revascularization for chronic stable angina. Analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989. Ann Intern Med. 1990;113:852-871.
28. Mark DB, Hlatky MA. Medical economics and the assessment of value in cardiovascular medicine: part II. Circulation. 2002;106:626-630. (Pubitemid 34827715)
29. Yang X, Li J, Shoptow S. Multiple partial imputation for longitudinal data with missing values in clinical trials. http://repositories.cdlib.org/ uclastat/ papers/2005010102. Accessed May 1, 2007.
30. Fairclough D. Design and Analysis of Quality of Life Studies in Clinical Trials. Boca Raton, FL: Chapman and Hall/CRC Press; 2002.